The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

In commencing a description of the mathematical sciences as practised and developed in Iran during ... Get access to the full version of this content by using one of the access options below. (Log in ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Reducing news to hard lines and side-taking leaves a lot of the story untold. Progress comes from challenging what we hear ...

Wittenberg University and Clark State College have moved classes online for the week as dishonest rumors about migrants ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...